Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

YishengBio Raises $130 Million for Immunomodulating Therapies

publication date: Feb 24, 2021

Beijing's YishengBio closed a $130 million Series B funding round to develop novel biotherapeutics for cancer and infectious diseases using its novel PIKA® immunomodulating technology. The company's YSJA™ rabies vaccine is the first alum-free lyophilized rabies vaccine launched in China. Its novel PIKA immunomodulating technology platform increases innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. The B round was co-led by Oceanpine and OrbiMed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here